throbber
Downloaded from https://academic.oup.com/femsyr/article/11/6/457/492132 by guest on 27 June 2024
`
`R E S E A R C H A R T I C L E
`Drug-resistant cassettes for the e⁄cient transformation ofCandida
`guilliermondiiwild-type strains
`Yoann Millerioux1, Marc Clastre1, Andrew J. Simkin1, Vincent Courdavault1, Emeline Marais1,
`Andriy A. Sibirny2,3, Thierry Noe¨ l4, Joe¨ l Cre` che1, Nathalie Giglioli-Guivarc’h1 & Nicolas Papon1
`
`1EA2106, Biomol ´ecules et Biotechnologies V ´eg ´etales, Facult ´e de Pharmacie, Universit ´e Franc¸ ois-Rabelais de Tours, Tours, France; 2Institute of Cell
`Biology, NAS of Ukraine, Lviv, Ukraine; 3Department of Biotechnology and Microbiology, University of Rzeszow, Rzeszow, Poland; and 4UMR 5234 CNRS
`Universit ´e Bordeaux 2, D ´epartement 2 Parasitologie et Mycologie Mol ´eculaire, Bordeaux, France
`
`Abstract
`
`Candida guilliermondii is an opportunistic emerging fungal agent of candidiasis
`often associated with oncology patients. This yeast also remains an interesting
`biotechnological model for the industrial production of value-added metabolites.
`The recent whole-genome sequencing of the C. guilliermondii ATCC 6260
`reference strain provides an interesting resource for elucidating new molecular
`events supporting pathogenicity, antifungal resistance and for exploring the
`potential of yeast metabolic engineering. In the present study, we designed an
`efficient transformation system for C. guilliermondii wild-type strains using both
`nourseothricin- and hygromycin B-resistant markers. To demonstrate the poten-
`tial of these drug-resistant cassettes, we carried out the disruption and the
`complementation of the C. guilliermondii FCY1 gene (which encodes cytosine
`deaminase) known to be associated with flucytosine sensitivity in yeast. These two
`new dominant selectable markers represent powerful tools to study the function of
`a large pallet of genes in this yeast of clinical and biotechnological interest.
`
`Correspondence: Nicolas Papon, EA2106,
`Biomol ´ecules et Biotechnologies V ´eg ´etales,
`Facult ´e de Pharmacie, Universit ´e Franc¸ ois-
`Rabelais de Tours, 31 avenue Monge, 37200
`Tours, France. Tel.: 133 2 47 36 72 13; fax:
`133 2 47 27 66 60; e-mail:
`nicolas.papon@univ-tours.fr
`
`Received 25 February 2011; revised 30 March
`2011; accepted 7 April 2011.
`Final version published online 9 May 2011.
`
`DOI:10.1111/j.1567-1364.2011.00731.x
`
`Editor: Andr ´e Goffeau
`
`Keywords
`transformation system; selectable markers;
`nourseothricin; hygromycin B; Candida
`guilliermondii.
`
`Introduction
`
`pounds such as xylitol (Mussatto et al., 2005), riboflavin
`(Boretsky et al., 2007), ethanol (Schirmer-Michel et al.,
`2008) or g-aminobutyric acid (Guo et al., 2009).
`The recent sequencing of the C. guilliermondii ATCC 6260
`reference strain whole genome clearly reflects the increasing
`interest of the scientific community in this yeast (Butler et al.,
`2009). All these aspects make C. guilliermondii an attractive
`model for elucidating new molecular events supporting patho-
`genicity, antifungal resistance and for exploring the potential
`of yeast metabolic engineering. The establishment of a con-
`venient transformation system becomes indispensable for
`genetic manipulations in this haploid species. A small number
`of metabolic gene markers are already available to carry out the
`genetic transformation of C. guilliermondii laboratory auxo-
`trophic strains (Boretsky et al., 1999, 2007; Millerioux et al.,
`2011). However, currently, the lack of dominant markers that
`confer resistance to various drugs precludes genetic studies in
`C. guilliermondii wild-type isolates.
`As observed in Candida albicans, the C. guilliermondii CTG
`codon encodes serine rather than leucine (referred as ‘CTG
`
`Candida guilliermondii (teleomorph Pichia guilliermondii) is
`an ascomycetous yeast widely distributed in nature and can
`be a common constituent of the normal human microbial
`communities. However, this fungal species is also an agent of
`candidiasis and has been described as an emerging pathogen
`characterized by its propensity to develop resistance to
`antifungal agents during treatment (Pfaller et al., 2006;
`Desnos-Ollivier et al., 2008; Savini et al., 2011). More
`precisely, recent studies specified that C. guilliermondii
`accounts for 1–3% of all candidemia and that most cases of
`C. guilliermondii
`infection are associated with oncology
`patients (Girmenia et al., 2006; Pfaller et al., 2006). Besides
`its clinical relevance, C. guilliermondii also remains an
`interesting biotechnological model for the industrial pro-
`duction of value-added metabolites (Leather, 2003). The
`extraordinary capacity of C. guilliermondii to metabolize C5
`sugars from hemicellulosic plant byproducts is nowadays
`studied by various teams in order to produce biocom-
`
`YEAST RESEARCH
`
`FEMS Yeast Res 11 (2011) 457–463
`
`c 2011 Federation of European Microbiological Societies
`Published by Blackwell Publishing Ltd. All rights reserved
`
`LCY Biotechnology Holding, Inc.
`Ex. 1042
`Page 1 of 7
`
`

`

`458
`
`Y. Millerioux et al.
`
`clade’), which is not the case for more distantly related species
`from the ‘whole-genome duplication’ clade including Saccharo-
`myces cerevisiae and Candida glabrata (Butler et al., 2009).
`Therefore, over the last decade, some effort was focused on the
`adaptation of drug-resistant genes (often with alternative
`leucine codons),
`initially used in Escherichia coli and S.
`cerevisiae, to favor their expression in species belonging to the
`CTG clade. Four Candida drug-resistant markers are currently
`0
`-monopho-
`available: the IMH3 marker encoding inosine 5
`sphate dehydrogenase, which confers resistance to mycophe-
`nolic acid (K¨ohler et al., 1997; Staib et al., 2000; Beckerman
`et al., 2001; G´acser et al., 2005), the ble marker encoding a
`glyoxalase, which confers resistance to the bleomycin/phleomy-
`cin/zeocin group (Tang et al., 2003; Dmytruk et al., 2006;
`Laplaza et al., 2006; Wang et al., 2006), the SAT-1 marker
`encoding nourseothricin acetyltransferase, which confers resis-
`tance to nourseothricin (Roemer et al., 2003; Reuss et al., 2004;
`Shen et al., 2005), and the HPH# marker encoding hygromycin
`phosphotransferase, which confers resistance to hygromycin B
`(Hara et al., 2000; Yehuda et al., 2001; Basso et al., 2010).
`In the present work, we adapted two of the aforemen-
`tioned selectable genes, nourseothricin and hygromycin B
`drug-resistant markers, to generate cassettes for their use in
`C. guilliermondii and we evaluated their applicability for the
`efficient genetic transformation of various wild-type strains.
`
`Materials and methods
`
`Strains and media
`
`Four C. guilliermondii wild-type strains from the Centre
`National de R´ef´erence Mycologie et Antifongiques of the
`Institut Pasteur (ODL9-811, ODL9-846, ODL12-1131 and
`MYCO55-BD), the whole genome sequenced reference strain
`from the American Type Culture Collection (ATCC 6260) and
`the ATCC 6260 derived ura5 mutant NP566U (Millerioux
`
`Table 1. Oligonucleotides
`
`et al., 2011) were used in our investigations. Yeast strains were
`routinely cultivated in liquid YPS medium (1% yeast extract,
`2% peptone, 2% sucrose) at 30 1C under agitation (150 r.p.m.).
`Nourseothricin (Werner BioAgents, stock solution prepared in
`1) and hygromycin B
`water at a concentration of 100 mg mL
`(Sigma-Aldrich, stock solution prepared in water at a concen-
`1) were added when necessary at the
`tration of 25 mg mL
`indicated concentration (see figure legends). YNB (0.67% yeast
`nitrogen base with ammonium sulfate and without amino
`acids, 2% sucrose) was supplemented or not with flucytosine
`(Sigma-Aldrich, stock solution prepared in water at a concen-
`1) as required. Solid media were pre-
`tration of 12.8 mg mL
`pared with 2% agar.
`
`PCR amplifications
`
`For plasmid constructions, SAT-1 and HPH# coding se-
`quences were amplified with Pfu (Promega). Yeast colony
`PCRs were performed as described in Akada et al. (2000)
`with GoTaq polymerase (Promega). The integration of the
`SAT-1 marker into nourseothricin-resistant colonies was
`confirmed by PCR using primers SAT1S and SAT2R (Table
`1). The integration of the HPH# marker into hygromycin B-
`resistant colonies was confirmed by PCR using primers
`HYGS1 and HYGR2 (Table 1). The FCY1-disrupted strains
`were first screened by PCR with primers FCY11 and FCY12
`(Table 1). The FCY1 gene disruption was then authenticated
`following PCRs using primers SAT1S or SAT2R with pri-
`mers located outside of the homology arms (not shown).
`The FCY1-complemented strains were screened by PCR
`using primers FCY11 and HYGR2. PCR conditions for
`amplification were those indicated by the supplier.
`
`Plasmids construction
`
`To construct plasmid pURA5-SAT-1, the 522 bp SAT-1
`coding sequence was amplified with primers SAT1S and
`
`Downloaded from https://academic.oup.com/femsyr/article/11/6/457/492132 by guest on 27 June 2024
`
`Sequence (5
`
`0
`
`0
`
`)
`
`–3
`
`CTGAGACTCGAGATGAAAATTTCGGTGATCCCTG
`CTGAGACTGCAGGGCGTCATCCTGTGCTCCCGAG
`CTGAGACTCGAGATGAAAAAGCCTGAACTCACCG
`CTGAGACTGCAGTTCCTTTGCCCTCGGACGAGTG
`GACTACAGTAAGGTGAACATCACC
`GTCACCCTCCATAGGGAGCACTGG
`CAGTGAGCTCGGAACGAGGTTTCC
`GCAAGCAGCAGACGCTACCAATGG
`GGTACCTCTAGAATCGATTGATCAGTCGACGGAGGAGTCTTCCGCAAGAGCC
`TGATCAATCGATTCTAGAGGTACCGGCGAGTTGTTGATGAAGATCTTG
`
`Sources/references
`
`This study
`This study
`This study
`This study
`Millerioux et al. (2011)
`Millerioux et al. (2011)
`Millerioux et al. (2011)
`Millerioux et al. (2011)
`This study
`This study
`
`Primers
`
`
`w
`
`
`w
`
`SAT1S
`SAT2R
`HYGS1
`HYGR2
`FCYS
`FCYR
`FCY11
`FCY12
`z
`PGKP5
`‰
`PGKT6
`
`
`The underlined sequence corresponds to the XhoI site.
`w
`The underlined sequence corresponds to the PstI site.
`z
`The underlined sequence corresponds to the KpnI, XbaI, ClaI, BclI and SalI sites.
`‰
`The underlined sequence corresponds to the KpnI, XbaI, ClaI and BclI sites.
`
`c 2011 Federation of European Microbiological Societies
`Published by Blackwell Publishing Ltd. All rights reserved
`
`FEMS Yeast Res 11 (2011) 457–463
`
`LCY Biotechnology Holding, Inc.
`Ex. 1042
`Page 2 of 7
`
`

`

`Drug-resistant cassettes for Candida guilliermondii
`
`459
`
`Downloaded from https://academic.oup.com/femsyr/article/11/6/457/492132 by guest on 27 June 2024
`
`Fig. 1. Transformation of the NP566U strain with pURA5-SAT-1 or pURA5-HPH#. (a) Schematic representation of pURA5-SAT-1. The XbaI unique site
`was used for linearization before transformation. (b) Schematic representation of pURA5-HPH#. (c) Nourseothricin and hygromycin B sensitivity of
`transformants. Nourseothricin and hygromycin B resistances tests were carried out for each strain by streaking ATCC 6260, NP566U and three
`
`1) or hygromycin B (500 mg mL1).
`representative clones from each transformation onto YPS supplemented or not with nourseothricin (150 mg mL
`
`SAT2R (Table 1) using the pSFS2 plasmid (Reuss et al.,
`2004) as a template. This fragment was digested at its
`extremities by XhoI and PstI and cloned between XhoI and
`PstI sites of pURA5-GFP (unpublished plasmid) after
`releasing of the yeGFP coding sequence, resulting in pURA5-
`SAT-1 (Fig. 1a). To obtain plasmid pURA5-HPH#, the
`1023 bp HPH# coding sequence was amplified with primers
`HYGS1 and HYGR2 (Table 1) using the pRS-HYG# plasmid
`(Hara et al., 2000) as a template. This fragment was digested
`at its extremities by XhoI and PstI and cloned between XhoI
`and PstI sites of pURA5-GFP after the release of the yeGFP
`coding sequence, resulting in pURA5-HPH# (Fig. 1b). To
`construct plasmid pG-SAT-1 and pG-HPH#, SAT-1 and
`HPH# (each bordered by C. guilliermondii phosphoglycerate
`kinase transcription-regulating sequences) were amplified
`with primers PGKP5 and PGKT6 (Table 1) and each cloned
`into pGEMT easy vector (Promega) (Fig. 2). To obtain
`0
`0
`FCY1, pG-
`FCY1-PGKpro-SAT-1-PGKter-3
`plasmid pG-5
`FCY1 (Millerioux et al., 2011) was digested with NarI, which
`is located at the center of the FCY1 coding sequence (Fig.
`3b). The resulting digested plasmid was ligated to the SAT-1
`fragment (bordered by C. guilliermondii phosphoglycerate
`kinase transcription-regulating sequences) released after the
`0
`FCY1-
`digestion of the pG-SAT-1 plasmid by ClaI. The 5
`0
`FCY1 disruption cassette was gen-
`PGKpro-SAT-1-PGKter-3
`erated using primers FCYS and FCYR (Table 1) and pG-
`0
`0
`FCY1 as a template. For
`FCY1-PGKpro-SAT-1-PGKter-3
`5
`
`constructing the complementation vector p-FCY1-HPH#
`(Fig. 4b), pG-FCY1 was digested with SpeI and ligated to the
`HPH# fragment (bordered by C. guilliermondii phosphogly-
`cerate kinase transcription-regulating sequences) released
`after the digestion of the pG-HPH# plasmid by XbaI.
`
`Yeast transformation
`
`Transformation of C. guilliermondii cells was performed
`using a lithium acetate procedure as described previously
`(Boretsky et al., 2007). After heat shock, cells were pelleted
`(3500 g, 10 min) and suspended in 3 mL YPS, incubated for
`5 h at 30 1C under agitation (150 r.p.m.), centrifuged
`(3500 g, 5 min), resuspended in 100 mL 1 M sucrose, plated
`onto selective medium and incubated at 30 1C for 3–5 days.
`
`Results and discussion
`
`Sensitivity of C. guilliermondiistrains to
`nourseothricin and hygromycin B
`
`We initiated this work by testing the sensitivity of
`C. guilliermondii strains toward nourseothricin and hygro-
`mycin B. Complete inhibition of
`the growth of all
`strains (ODL9-811, ODL9-846, ODL12-1131, MYCO55-
`BD and ATCC 6260) was observed (after 4 days of culture)
`1 nourseothricin or
`on YPS plates containing 150 mg mL
`1 hygromycin B.
`500 mg mL
`
`FEMS Yeast Res 11 (2011) 457–463
`
`c 2011 Federation of European Microbiological Societies
`Published by Blackwell Publishing Ltd. All rights reserved
`
`LCY Biotechnology Holding, Inc.
`Ex. 1042
`Page 3 of 7
`
`

`

`460
`
`Y. Millerioux et al.
`
`Downloaded from https://academic.oup.com/femsyr/article/11/6/457/492132 by guest on 27 June 2024
`
`Fig. 2. (a) Selection and characterization of nourseothricin-resistant colonies after the transformation of Candida guilliermondii with plasmid pG-SAT-1.
`
`single site restriction enzymes) and representative plates of selection for nourseothricin resistance 4 days (30 1C) after
`A representation of pG-SAT-1 (
`the transformation of C. guilliermondii cells (ODL9-846) with sterile water (control) or 5 mg of linearized pG-SAT-1 are shown. The ApaI unique site was
`used for linearization before transformation. Yeast colony PCR on a subset of 15 randomly selected clones was performed using specific primers (SAT1S
`and SAT2R) to amplify the SAT-1 sequence. (b) Selection and characterization of hygromycin B-resistant colonies after transformation with plasmid pG-
`HPH#. A representation of pG-HPH# and representative plates of selection for hygromycin B resistance 4 days after the transformation of C.
`guilliermondii cells (ODL9-846) with sterile water (control) or 5 mg of linearized pG-HPH# are shown. The ApaI unique site was used for linearization
`before transformation. Yeast colony PCR on a subset of 15 randomly selected clones was performed using specific primers (HYGS1 and HYGR2) to
`amplify the HPH# sequence. Single site restriction enzymes are marked in bold with an asterisk.
`
`Expression of codon-optimized SAT-1and HPH#
`genes in C. guilliermondii
`
`
`In a first series of experiments, we failed to obtain anya first series of experiments, we failed to obtain any
`nourseothricin- and hygromycin B-resistant transformants
`nourseothricin- and hygromycin B-resistant transformants
`when we attempted to transform C. guilliermondii strains
`when we attempted to transform C. guilliermondii strains
`with 0.2, 1 or 5 mg of pSFS2 plasmid (Reuss et al., 2004) and
`with 0.2, 1 or 5 mg of pSFS2 plasmid (Reuss et al., 2004) and
`pRS-HYG# plasmid (Hara et al., 2000), respectively. ThepRS-HYG# plasmid (Hara et al., 2000), respectively. The
`
`SAT-TT 1 coding sequence is under
`the control of
`the
`SAT-1 coding sequence is under
`the control of
`the
`C. albicans ACT1 promoter and the C. albicans URA3
`C. albicans ACT1 promoter and the C. albicans URA3
`terminator in plasmid pSFS2 (Reuss et al., 2004), whereas
`terminator in plasmid pSFS2 (Reuss et al., 2004), whereas
`the HPH# coding sequence is bordered by the Candidathe HPH#HH coding sequence is bordered by the Candida
`
`tropicalis phosphoglycerate kinase promoter and terminator
`tropicalis phosphoglycerate kinase promoter and terminator
`(Hara et al., 2000). It is thus likely that these heterologous
`(Hara et al., 2000). It is thus likely that these heterologous
`transcription-regulating sequences preclude the expression
`transcription-regulating sequences preclude the expression
`of SAT-1 and HPH# in C. guilliermondii.of SAT-TT 1 and HPH#HH in C. guilliermondii.
`
`For this reason, we placed SAT-1 and HPH# under the
`control
`of C.
`guilliermondii
`transcription-regulating
`sequences. We constructed two plasmids composed of (1)
`the pGEM-T backbone vector; (2) the recently developed
`C. guilliermondii URA5 selection marker (Millerioux et al.,
`2011);
`(3) a 626-bp sequence corresponding to the
`
`C. guilliermondii phosphoglycerate kinase 1 (PGK) gene
`promoter (PGKpro); (4) a codon-optimized SAT-1 or HPH#
`coding sequence (SAT-1 in pURA5-SAT-1 and HPH# in
`pURA5-HPH#); and (5) a 659-bp sequence corresponding
`to the C. guilliermondii PGK terminator (PGKter) (Fig. 1). To
`demonstrate the capacity of these constructs to confer
`nourseothricin or hygromycin B resistance in C. guillier-
`mondii, we transformed to prototrophy the NP566U strain
`(an ura5 mutant derived from ATCC 6260, Millerioux et al.,
`2011) with 500 ng of linearized pURA5-SAT-1 or pURA5-
`HPH#. More than 90% of the clones selected on YNB
`medium after transformation with pURA5-SAT-1 were
`nourseothricin resistant and similar percentages of the
`clones selected on YNB medium after transformation with
`pURA5-HPH# were hygromycin B resistant (Fig. 1). These
`data indicate that PGK transcription-regulating sequences
`allow a constitutive expression of SAT-1 and HPH# that
`confers nourseothricin and hygromycin B resistance to
`C. guilliermondii cells, respectively. Furthermore,
`these
`results show that SAT-1 does not confer hygromycin B
`resistance and HPH# does not confer nourseothricin resis-
`tance in this species.
`
`c 2011 Federation of European Microbiological Societies
`Published by Blackwell Publishing Ltd. All rights reserved
`
`FEMS Yeast Res 11 (2011) 457–463
`
`LCY Biotechnology Holding, Inc.
`Ex. 1042
`Page 4 of 7
`
`

`

`Drug-resistant cassettes for Candida guilliermondii
`
`461
`
`Downloaded from https://academic.oup.com/femsyr/article/11/6/457/492132 by guest on 27 June 2024
`
`Fig. 3. Disruption of the Candida guilliermondii
`FCY1 gene using the SAT-1 marker. (a) For each
`strain derived from the MYCO55-BD transfor-
`0
`FCY1-PGKpro-SAT-1-PGKter-
`mation with the 5
`0
`FCY1 cassette, the FCY1 locus was analyzed by
`3
`yeast colony PCR using FCY11 and FCY12 pri-
`mers. Five microliters of washed cells (105 cells)
`were spotted onto YPS supplemented or not
`1 nourseothricin. Flucytosine
`with 150 mg mL
`resistance was shown by spotting cells onto
`1 flucytosine.
`YNB supplemented with 8 mg mL
`(b) Schematic representation of the resident loci
`(the hatched box corresponds to an intron
`identified in the FCY1 coding sequence).
`
`Direct transformation of C. guilliermondiiusing
`SAT-1and HPH# dominant markers
`
`With the goal to facilitate molecular manipulations, we
`constructed two plasmids, pG-SAT-1 and pG-HPH#, har-
`boring the PGKpro-SAT-1-PGKter or PGKpro-HPH#-PGKter
`cassettes bordered by two multiple cloning sites (Fig. 2). To
`test whether the two cassettes could be used directly as
`selectable markers in C. guilliermondii strains, we trans-
`formed the ODL9-846 strain with 0.2, 1 or 5 mg of linearized
`pG-SAT-1 or pG-HPH#. No resistant clones were selected
`when the ODL9-846 strain was transformed with 0.2 or 1 mg
`of pG-SAT-1 or pG-HPH#. However, 50–200 nourseothri-
`cin- and hygromycin B-resistant clones were obtained when
`the ODL9-846 strain was transformed with 5 mg of pG-SAT-
`1 and pG-HPH#, respectively (Fig. 2).
`To verify that nourseothricin or hygromycin B resistance
`derived from the integration of the cassettes, we performed
`yeast colony PCR on a subset of 15 randomly selected clones
`using specific primers to amplify SAT-1 or HPH# sequences.
`As shown in Fig. 2, all screened nourseothricin- or hygro-
`mycin B-resistant colonies displayed PCR products con-
`formable with the presence of the SAT-1 or the HPH#
`sequence, respectively. These results suggest that SAT-1 and
`HPH# markers were incorporated into the genome of the
`ODL9-846 strain and provide evidence that PGKpro-SAT-1-
`PGKter or PGKpro-HPH#-PGKter cassettes could be used
`directly as dominant selection markers in C. guilliermondii
`wild-type strains.
`
`Disruption of the FCY1gene: an example of gene
`knockout in C. guilliermondiiwild-type strains
`using the SAT-1marker
`
`To demonstrate the potential of these new drug-resistant
`markers in C. guilliermondii, we attempted, as an example,
`the disruption and subsequently the complementation of a
`gene that allows for easy mutant phenotype screening. We
`chose the FCY1 gene encoding cytosine deaminase (involved
`in the pyrimidine salvage pathway) because the fcy1 deletion
`in C. guilliermondii leads to strong flucytosine resistance
`(Millerioux et al., 2011).
`The SAT-1 marker was first chosen to disrupt the FCY1
`gene in the five C. guilliermondii wild-type strains. For this
`0
`0
`FCY1 fragment
`FCY1-PGKpro-SAT-1-PGKter-3
`purpose, a 5
`0
`0
`and 3
`FCY1 homologous arms was
`with 2000 bp of the 5
`generated by PCR and used to transform the C. guilliermon-
`dii strains. Transformants derived from each host strain
`1 nourseothricin-containing YPS
`(selected onto 150 mg mL
`plates) were subjected to flucytosine sensitivity testing and
`to PCR analysis. For all the screened clones, the flucytosine
`resistance phenotype was concomitant with homologous
`0
`0
`FCY1
`FCY1-PGKpro-SAT-1-PGKter-3
`integration of
`the 5
`cassette at the FCY1 locus (genotype fcy1SAT-1). Interestingly,
`PCR and phenotypic analyses showed that the FCY1 gene
`had been replaced by homologous recombination in all the
`five transformed C. guilliermondii strains with variable
`targeting frequencies (Table 2). The best percentage of
`homologous targeting was obtained with the MYCO55-BD
`
`FEMS Yeast Res 11 (2011) 457–463
`
`c 2011 Federation of European Microbiological Societies
`Published by Blackwell Publishing Ltd. All rights reserved
`
`LCY Biotechnology Holding, Inc.
`Ex. 1042
`Page 5 of 7
`
`

`

`Downloaded from https://academic.oup.com/femsyr/article/11/6/457/492132 by guest on 27 June 2024
`
`462
`
`Y. Millerioux et al.
`
`Fig. 4. Complementation of the fcy1SAT-1-
`disrupted allele using the HPH# marker. (a) For
`each strain derived from the transformation of a
`representative MYCO55-BD fcy1SAT-1 mutant
`with p-FCY1-HPH#, the integration of the
`complementation plasmid was analyzed by yeast
`colony PCR using FCY11 and HYGR2 primers.
`Five microliters of washed cells (105 cells) were
`spotted onto YPS supplemented or not with
`1 hygromycin B. Flucytosine resis-
`500 mg mL
`tance was shown by spotting cells onto YNB
`1 flucytosine.
`supplemented with 8 mg mL
`F: MYCO55-BD fcy1SAT-1parental strain used
`for transformation. (b) Schematic representation
`of the complementation plasmid. The XbaI
`unique site was used for linearization before
`transformation.
`
`Table 2. Homologous targeting frequencies of Candida guilliermondii
`0
`0
`FCY1
`FCY1-PGKpro-SAT-1-PGKter-3
`strains
`transformed with the 5
`disruption cassette
`
`No. of
`transformants
`
`No. of flucytosine-
`resistant clones
`
`Homologous
`targeting
`frequency (%)
`
`191
`137
`42
`15
`82
`
`6
`4
`2
`3
`3
`
`3.1
`2.9
`4.8
`20
`3.7
`
`Strains
`
`ODL9-811
`ODL9-846
`ODL12-1131
`MYCO55-BD
`ATCC 6260
`
`strain (flucytosine sensitivity testing and PCR analysis are
`given as an example in Fig. 3). For the remaining nourseo-
`thricin-resistant and flucytosine-sensitive transformants, it
`is highly likely that they were derived from gene replacement
`at the PGK locus or ectopic integration (not studied).
`
`The use of the HPH# marker for
`complementation of the fcy1 null allele
`
`In order to validate the capacity of the second available drug-
`resistant marker, i.e. HPH# to carry out the complementation
`of the fcy1SAT-1-disrupted allele, we constructed a plasmid that
`contained both the FCY1 wild-type allele and the PGKpro-
`HPH#-PGKter cassette (p-FCY1-HPH#, Fig. 4). This comple-
`mentation vector was linearized and was used to transform
`two fcy1SAT-1 mutants (one derived from ODL9-811 and the
`other derived from MYCO55-BD). Transformants derived
`1 hygromycin
`from both host strains (selected onto 500 mg mL
`B-containing YPS plates) were subjected to flucytosine sensi-
`tivity testing and to PCR analysis. For all screened clones, the
`restored flucytosine
`sensitivity phenotype
`(30–50% of
`screened transformants) was concomitant with the integration
`of the complementation plasmid (Fig. 4).
`
`Conclusion
`
`In summary, the present study describes the development of
`an efficient transformation system for C. guilliermondii
`wild-type strains based on two new drug-resistant markers.
`The hygromycin B-resistant markers were already used as
`the selection gene in various yeast and filamentous species
`(for a review, see Weld et al., 2006). Nevertheless, nourseo-
`thricin-resistant markers are rarely used for the transforma-
`tion of fungi (for a review, see Basso et al., 2010). Although
`our results suggest, as revealed in other previous studies
`(Boretsky et al., 2007; Millerioux et al., 2011), that trans-
`formed DNA is predominantly randomly integrated in
`C. guilliermondii, this work firmly demonstrates the poten-
`tial of these two new selection markers to perform gene
`disruption/complementation in wild-type strains. We con-
`clude that
`they represent powerful
`tools to study the
`function of a large pallet of genes, especially involved in
`antifungal resistance, pathogenicity, and for metabolic en-
`gineering in this emerging yeast.
`
`Acknowledgements
`
`We thank Atsuo Tanaka (Laboratory of Applied Biological
`Chemistry, Kyoto University, Japan) and Joachim Morschh¨au-
`ser (Institut f¨ur Molekulare Infektionsbiologie, Universit¨at
`W¨urzburg, Deutschland) for providing pRS-HYG# and pSFS2,
`respectively. We acknowledge Franc¸oise Dromer and Marie
`Desnos-Ollivier (National Reference Center for Mycoses and
`Antifungals, Institut Pasteur, Paris, France) for providing C.
`guilliermondii strains. We also thank Martin Goldway (Galilee
`Technological Center, Tel-Hai Academic College, Israel) for his
`precious advice. We acknowledge the Broad Institute Fungal
`Genome Initiative for making the complete genome sequence
`of C. guilliermondii available. We thank ‘Le STUDIUM’
`(Centre region, France) for the financial support of A.J.S.
`
`c 2011 Federation of European Microbiological Societies
`Published by Blackwell Publishing Ltd. All rights reserved
`
`FEMS Yeast Res 11 (2011) 457–463
`
`LCY Biotechnology Holding, Inc.
`Ex. 1042
`Page 6 of 7
`
`

`

`Downloaded from https://academic.oup.com/femsyr/article/11/6/457/492132 by guest on 27 June 2024
`
`Drug-resistant cassettes for Candida guilliermondii
`
`463
`
`References
`
`Akada R, Murakane T & Nishizawa Y (2000) DNA extraction
`method for screening yeast clones by PCR. Biotechniques 28:
`668–674.
`Basso LR Jr, Bartiss A, Mao Y, Gast CE, Coelho PS, Snyder M &
`Wong B (2010) Transformation of Candida albicans with a
`synthetic hygromycin B resistance gene. Yeast 27: 1039–1048.
`Beckerman J, Chibana H, Turner J & Magee PT (2001) Single-copy
`IMH3 allele is sufficient to confer resistance to mycophenolic
`acid in Candida albicans and to mediate transformation of
`clinical Candida species. Infect Immun 69: 108–114.
`Boretsky Y, Voronovsky A, Liuta-Tehlivets O, Hasslacher M,
`Kohlwein SD & Shavlovsky GM (1999) Identification of an
`ARS element and development of a high efficiency
`transformation system for Pichia guilliermondii. Curr Genet
`36: 215–221.
`Boretsky YR, Pynyaha YV, Boretsky VY, Kutsyaba VI, Protchenko
`OV, Philpott CC & Sibirny AA (2007) Development of a
`transformation system for gene knock-out in the flavinogenic
`yeast Pichia guilliermondii. J Microbiol Meth 70: 13–19.
`Butler G, Rasmussen MD, Lin MF et al. (2009) Evolution of
`pathogenicity and sexual reproduction in eight Candida
`genomes. Nature 459: 657–662.
`Desnos-Ollivier M, Ragon M, Robert V, Raoux D, Gantier JC &
`Dromer F (2008) Debaryomyces hansenii (Candida famata), a
`rare human fungal pathogen often misidentified as Pichia
`guilliermondii (Candida guilliermondii). J Clin Microbiol 46:
`3237–3242.
`Dmytruk KV, Voronovsky AY & Sibirny AA (2006) Insertion
`mutagenesis of the yeast Candida famata (Debaryomyces
`hansenii) by random integration of linear DNA fragments.
`Curr Genet 50: 183–191.
`G´acser A, Salomon S & Sch¨afer W (2005) Direct transformation
`of a clinical isolate of Candida parapsilosis using a dominant
`selection marker. FEMS Microbiol Lett 245: 117–121.
`Girmenia C, Pizzarelli G, Cristini F, Barchiesi F, Spreghini E,
`Scalise G & Martino P (2006) Candida guilliermondii fungemia
`in patients with hematologic malignancies. J Clin Microbiol 44:
`2458–2464.
`Guo XF, Aoki H, Hagiwara T, Masuda K & Watabe S (2009)
`Identification of high gamma-aminobutyric acid producing
`marine yeast strains by physiological and biochemical
`characteristics and gene sequence analyses. Biosci Biotech Bioch
`73: 1527–1534.
`Hara A, Ueda M, Misawa S, Matsui T, Furuhashi K & Tanaka A
`(2000) A mutated hygromycin resistance gene is functional in
`the n-alkane-assimilating yeast Candida tropicalis. Arch
`Microbiol 173: 187–192.
`K¨ohler GA, White TC & Agabian N (1997) Overexpression of a
`cloned IMP dehydrogenase gene of Candida albicans confers
`resistance to the specific inhibitor mycophenolic acid. J
`Bacteriol 179: 2331–2338.
`Laplaza JM, Rivas Torres B, Jin YS & Jeffries TW (2006) Sh ble and
`Cre adapted for functional genomics and metabolic
`engineering of Pichia stipitis. Enzyme Microb Tech 38: 741–747.
`
`Leather TD (2003) Bioconversions of maize residues to value-
`added coproducts using yeast-like fungi. FEMS Yeast Res 3:
`133–140.
`Millerioux Y, Clastre M, Simkin AJ, Marais E, Sibirny AA, Noe¨l T,
`Cre`che J, Giglioli-Guivarc’h N & Papon N (2011)
`Development of a URA5 integrative cassette for gene
`disruption in the Candida guilliermondii ATCC 6260 strain.
`J Microbiol Meth 84: 355–358.
`Mussatto SI, Santos JC, Filho WC & Silva SS (2005) Purification
`of xylitol from fermented hemicellulosic hydrolyzate using
`liquid–liquid extraction and precipitation techniques.
`Biotechnol Lett 27: 1113–1115.
`Pfaller MA, Diekema DJ, Mendez M, Kibbler C, Erzsebet P, Chang
`SC, Gibbs DL & Newell VA (2006) Candida guilliermondii, an
`opportunistic fungal pathogen with decreased susceptibility to
`fluconazole: geographic and temporal trends from the
`ARTEMIS DISK antifungal surveillance program. J Clin
`Microbiol 44: 3551–3556.
`Reuss O, Vik A, Kolter R & Morschh¨auser J (2004) The SAT1
`flipper, an optimized tool for gene disruption in Candida
`albicans. Gene 341: 119–127.
`Roemer T, Jiang B, Davison J et al. (2003) Large-scale essential
`gene identification in Candida albicans and applications to
`antifungal drug discovery. Mol Microbiol 50: 167–181.
`Savini V, Catavitello C, Onofrillo D, Masciarelli G, Astolfi D,
`Balbinot A, Febbo F, D’Amario C & D’Antonio D (2011) What
`do we know about Candida guilliermondii? A voyage
`throughout past and current literature about this emerging
`yeast. Mycoses, DOI: 10.1111/j.1439-0507.2010.01960.x.
`Schirmer-Michel AC, Floˆ res SH, Hertz PF, Matos GS & Ayub MA
`(2008) Production of ethanol from soybean hull hydrolysate
`by osmotolerant Candida guilliermondii NRRL Y-2075.
`Bioresource Technol 99: 2898–2904.
`Shen J, Guo W & K¨ohler JR (2005) CaNAT1, a heterologous
`dominant selectable marker for transformation of Candida
`albicans and other pathogenic Candida species. Infect Immun
`73: 1239–1242.
`Staib P, Michel S, K¨ohler G & Morschh¨auser J (2000) A molecular
`genetic system for the pathogenic yeast Candida dubliniensis.
`Gene 242: 393–398.
`Tang SJ, Sun KH, Sun GH, Chang TY, Wu WL & Lee GC (2003)
`A transformation system for the nonuniversal CUG(Ser)
`codon usage species Candida rugosa. J Microbiol Meth 52:
`231–238.
`Wang X, Li G, Deng Y, Yu X & Chen F (2006) A site-directed
`integration system for the nonuniversal CUG(Ser) codon
`usage species Pichia farinosa by electroporation. Arch Microbiol
`184: 419–424.
`Weld RJ, Plummer KM, Carpenter MA & Ridgway HJ (2006)
`Approaches to functional genomics in filamentous fungi. Cell
`Res 16: 31–44.
`Yehuda H, Droby S, Wisniewski M & Goldway M (2001) A
`transformation system for the biocontrol yeast, Candida
`oleophila, based on hygromycin B resistance. Curr Genet 40:
`282–287.
`
`FEMS Yeast Res 11 (2011) 457–463
`
`c 2011 Federation of European Microbiological Societies
`Published by Blackwell Publishing Ltd. All rights reserved
`
`LCY Biotechnology Holding, Inc.
`Ex. 1042
`Page 7 of 7
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket